Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Papillomavirus Infections | 31 | 2024 | 194 | 9.980 |
Why?
|
| Anus Neoplasms | 24 | 2024 | 37 | 9.610 |
Why?
|
| Uterine Cervical Neoplasms | 15 | 2024 | 300 | 6.030 |
Why?
|
| Papillomavirus Vaccines | 11 | 2024 | 93 | 5.800 |
Why?
|
| HIV Infections | 16 | 2024 | 791 | 2.940 |
Why?
|
| Incidence | 21 | 2024 | 1603 | 2.770 |
Why?
|
| Sexual and Gender Minorities | 7 | 2024 | 44 | 2.630 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2024 | 629 | 2.470 |
Why?
|
| Parents | 3 | 2021 | 312 | 1.820 |
Why?
|
| Papillomaviridae | 17 | 2024 | 104 | 1.800 |
Why?
|
| Vaccination | 7 | 2024 | 189 | 1.790 |
Why?
|
| United States | 29 | 2024 | 7367 | 1.660 |
Why?
|
| Alphapapillomavirus | 2 | 2022 | 17 | 1.560 |
Why?
|
| Homosexuality, Male | 12 | 2024 | 34 | 1.430 |
Why?
|
| Female | 52 | 2024 | 38074 | 1.400 |
Why?
|
| Intention | 2 | 2021 | 80 | 1.400 |
Why?
|
| Humans | 67 | 2024 | 68618 | 1.200 |
Why?
|
| Vulvar Neoplasms | 3 | 2022 | 24 | 1.190 |
Why?
|
| Anus Diseases | 2 | 2023 | 5 | 1.120 |
Why?
|
| Cross-Sectional Studies | 14 | 2024 | 2279 | 1.090 |
Why?
|
| Neoplasms | 3 | 2022 | 1667 | 1.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2022 | 123 | 1.010 |
Why?
|
| Carcinoma in Situ | 2 | 2022 | 47 | 0.980 |
Why?
|
| Nutrition Surveys | 4 | 2023 | 208 | 0.970 |
Why?
|
| Income | 2 | 2024 | 167 | 0.950 |
Why?
|
| Male | 37 | 2024 | 37321 | 0.930 |
Why?
|
| Middle Aged | 28 | 2024 | 21147 | 0.910 |
Why?
|
| Prevalence | 10 | 2023 | 1619 | 0.900 |
Why?
|
| Aged | 20 | 2024 | 14862 | 0.890 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2022 | 94 | 0.890 |
Why?
|
| Early Detection of Cancer | 15 | 2024 | 454 | 0.880 |
Why?
|
| Anal Canal | 8 | 2023 | 28 | 0.850 |
Why?
|
| Cost of Illness | 2 | 2024 | 206 | 0.810 |
Why?
|
| Guideline Adherence | 2 | 2021 | 287 | 0.800 |
Why?
|
| Global Health | 1 | 2022 | 136 | 0.800 |
Why?
|
| Folic Acid | 2 | 2020 | 123 | 0.790 |
Why?
|
| Adult | 22 | 2024 | 21403 | 0.780 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 33 | 0.770 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 42 | 0.770 |
Why?
|
| Vaccination Refusal | 1 | 2021 | 1 | 0.760 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2021 | 62 | 0.760 |
Why?
|
| Mass Screening | 5 | 2024 | 843 | 0.750 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 446 | 0.740 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2020 | 157 | 0.740 |
Why?
|
| Suicide | 1 | 2021 | 116 | 0.720 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 123 | 0.720 |
Why?
|
| Risk Factors | 11 | 2024 | 5731 | 0.710 |
Why?
|
| Puerto Rico | 7 | 2024 | 31 | 0.690 |
Why?
|
| Mortality | 1 | 2020 | 163 | 0.670 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 1536 | 0.630 |
Why?
|
| Health Expenditures | 2 | 2023 | 170 | 0.620 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 62 | 0.620 |
Why?
|
| Cancer Survivors | 1 | 2019 | 146 | 0.570 |
Why?
|
| SEER Program | 3 | 2024 | 153 | 0.560 |
Why?
|
| Risk Assessment | 3 | 2020 | 2007 | 0.550 |
Why?
|
| Dietary Supplements | 1 | 2019 | 332 | 0.540 |
Why?
|
| Young Adult | 7 | 2024 | 5717 | 0.510 |
Why?
|
| Sexual Behavior | 4 | 2023 | 183 | 0.490 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 940 | 0.490 |
Why?
|
| Adolescent | 7 | 2024 | 8912 | 0.450 |
Why?
|
| Retrospective Studies | 9 | 2023 | 7277 | 0.410 |
Why?
|
| Obesity | 1 | 2019 | 1076 | 0.400 |
Why?
|
| Pandemics | 3 | 2024 | 352 | 0.370 |
Why?
|
| Registries | 3 | 2024 | 733 | 0.360 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 4848 | 0.350 |
Why?
|
| Age Factors | 4 | 2022 | 1864 | 0.340 |
Why?
|
| Human papillomavirus 16 | 4 | 2024 | 23 | 0.330 |
Why?
|
| HIV | 3 | 2024 | 56 | 0.320 |
Why?
|
| Water | 2 | 2019 | 230 | 0.300 |
Why?
|
| Human papillomavirus 18 | 3 | 2021 | 5 | 0.280 |
Why?
|
| Insulin | 2 | 2019 | 619 | 0.260 |
Why?
|
| Sex Distribution | 2 | 2024 | 274 | 0.260 |
Why?
|
| Smoking | 3 | 2022 | 1452 | 0.260 |
Why?
|
| North America | 1 | 2024 | 112 | 0.240 |
Why?
|
| Tongue Neoplasms | 1 | 2024 | 29 | 0.230 |
Why?
|
| Cohort Studies | 2 | 2021 | 2358 | 0.230 |
Why?
|
| Kentucky | 1 | 2023 | 13 | 0.230 |
Why?
|
| Canada | 1 | 2024 | 267 | 0.230 |
Why?
|
| Case-Control Studies | 4 | 2021 | 1553 | 0.230 |
Why?
|
| Sexually Transmitted Diseases, Viral | 2 | 2021 | 4 | 0.230 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2800 | 0.220 |
Why?
|
| Genitalia | 1 | 2023 | 5 | 0.220 |
Why?
|
| Medicine | 1 | 2023 | 52 | 0.220 |
Why?
|
| Sarcoma, Kaposi | 1 | 2022 | 25 | 0.210 |
Why?
|
| Social Media | 1 | 2024 | 59 | 0.210 |
Why?
|
| Homocysteine | 2 | 2020 | 28 | 0.210 |
Why?
|
| Neoplasm Staging | 1 | 2024 | 800 | 0.200 |
Why?
|
| Earthquakes | 1 | 2021 | 4 | 0.200 |
Why?
|
| Atypical Squamous Cells of the Cervix | 1 | 2021 | 1 | 0.200 |
Why?
|
| HIV Seronegativity | 1 | 2021 | 11 | 0.200 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2019 | 109 | 0.200 |
Why?
|
| Mouth Diseases | 1 | 2021 | 39 | 0.200 |
Why?
|
| Potentially Inappropriate Medication List | 1 | 2021 | 3 | 0.190 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 64 | 0.190 |
Why?
|
| Mastectomy | 1 | 2021 | 57 | 0.190 |
Why?
|
| Cyclonic Storms | 1 | 2021 | 59 | 0.190 |
Why?
|
| HIV Seropositivity | 1 | 2021 | 66 | 0.190 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2021 | 73 | 0.190 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2021 | 98 | 0.180 |
Why?
|
| Datasets as Topic | 1 | 2020 | 53 | 0.180 |
Why?
|
| Probability | 1 | 2021 | 245 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 101 | 0.180 |
Why?
|
| Urban Population | 1 | 2021 | 255 | 0.180 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 111 | 0.180 |
Why?
|
| History, 21st Century | 1 | 2020 | 127 | 0.180 |
Why?
|
| Smoking Cessation | 2 | 2019 | 1034 | 0.170 |
Why?
|
| Survivors | 2 | 2019 | 256 | 0.170 |
Why?
|
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2019 | 4 | 0.170 |
Why?
|
| Depressive Disorder, Major | 1 | 2023 | 439 | 0.170 |
Why?
|
| Hypertension | 2 | 2019 | 1535 | 0.160 |
Why?
|
| Genital Neoplasms, Female | 1 | 2019 | 38 | 0.160 |
Why?
|
| Vitamin B Complex | 1 | 2019 | 26 | 0.160 |
Why?
|
| Health Surveys | 1 | 2021 | 489 | 0.160 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 561 | 0.160 |
Why?
|
| Ambulatory Care | 1 | 2021 | 340 | 0.160 |
Why?
|
| Vaginal Neoplasms | 1 | 2018 | 21 | 0.160 |
Why?
|
| Penile Neoplasms | 1 | 2018 | 12 | 0.160 |
Why?
|
| Antirheumatic Agents | 1 | 2019 | 59 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 3259 | 0.160 |
Why?
|
| Poisson Distribution | 1 | 2018 | 85 | 0.160 |
Why?
|
| Rural Population | 1 | 2021 | 398 | 0.150 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 362 | 0.150 |
Why?
|
| Patient Participation | 1 | 2019 | 146 | 0.150 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2018 | 106 | 0.150 |
Why?
|
| Cell Phone | 1 | 2018 | 44 | 0.150 |
Why?
|
| Logistic Models | 1 | 2021 | 1420 | 0.140 |
Why?
|
| Child | 3 | 2023 | 6405 | 0.140 |
Why?
|
| Medicare | 3 | 2023 | 319 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 504 | 0.140 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 425 | 0.140 |
Why?
|
| Counseling | 1 | 2018 | 280 | 0.130 |
Why?
|
| Blood Pressure | 2 | 2019 | 1451 | 0.130 |
Why?
|
| Survival Rate | 1 | 2019 | 1056 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2019 | 867 | 0.130 |
Why?
|
| Telemedicine | 1 | 2023 | 700 | 0.130 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 498 | 0.120 |
Why?
|
| Comorbidity | 1 | 2019 | 1426 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2017 | 249 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 767 | 0.120 |
Why?
|
| Proteins | 1 | 2018 | 474 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2019 | 703 | 0.110 |
Why?
|
| Hospitalization | 1 | 2019 | 978 | 0.110 |
Why?
|
| Ethanol | 1 | 2019 | 893 | 0.110 |
Why?
|
| Heart Failure | 1 | 2021 | 1180 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 1173 | 0.090 |
Why?
|
| Smokers | 2 | 2021 | 200 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 931 | 0.070 |
Why?
|
| Stroke | 1 | 2019 | 2163 | 0.070 |
Why?
|
| Vaginal Smears | 1 | 2023 | 79 | 0.060 |
Why?
|
| Private Sector | 1 | 2023 | 19 | 0.060 |
Why?
|
| Age Distribution | 1 | 2024 | 320 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 3705 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2023 | 47 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2023 | 36 | 0.050 |
Why?
|
| Physicians, Family | 1 | 2023 | 83 | 0.050 |
Why?
|
| Toxoids | 1 | 2022 | 3 | 0.050 |
Why?
|
| Postmenopause | 1 | 2023 | 93 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 29 | 0.050 |
Why?
|
| Vagina | 1 | 2022 | 88 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2023 | 129 | 0.050 |
Why?
|
| Human papillomavirus 11 | 1 | 2021 | 1 | 0.050 |
Why?
|
| Human papillomavirus 6 | 1 | 2021 | 1 | 0.050 |
Why?
|
| Sitagliptin Phosphate | 1 | 2021 | 4 | 0.050 |
Why?
|
| Wisconsin | 1 | 2021 | 31 | 0.050 |
Why?
|
| Sotalol | 1 | 2021 | 6 | 0.050 |
Why?
|
| Diltiazem | 1 | 2021 | 26 | 0.050 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2021 | 14 | 0.050 |
Why?
|
| Citalopram | 1 | 2021 | 30 | 0.050 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2021 | 54 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2022 | 201 | 0.050 |
Why?
|
| Self Care | 1 | 2023 | 253 | 0.050 |
Why?
|
| Heterosexuality | 1 | 2021 | 17 | 0.050 |
Why?
|
| Genotype | 1 | 2023 | 786 | 0.050 |
Why?
|
| Sexual Partners | 1 | 2021 | 106 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2021 | 77 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2021 | 138 | 0.050 |
Why?
|
| Electrocoagulation | 1 | 2020 | 35 | 0.040 |
Why?
|
| Coinfection | 1 | 2020 | 30 | 0.040 |
Why?
|
| Causality | 1 | 2020 | 82 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 468 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 540 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 468 | 0.040 |
Why?
|
| Genitalia, Female | 1 | 2019 | 20 | 0.040 |
Why?
|
| Medicaid | 1 | 2021 | 302 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 240 | 0.040 |
Why?
|
| Health Literacy | 1 | 2019 | 63 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 197 | 0.040 |
Why?
|
| Diuretics | 1 | 2019 | 97 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 622 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 152 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 202 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1664 | 0.040 |
Why?
|
| Quantum Theory | 1 | 2018 | 21 | 0.040 |
Why?
|
| Hydrogen Bonding | 1 | 2018 | 67 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 792 | 0.040 |
Why?
|
| Protein Stability | 1 | 2018 | 90 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 117 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 1038 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2017 | 47 | 0.040 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2019 | 171 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2017 | 79 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 649 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 371 | 0.040 |
Why?
|
| Poverty | 1 | 2018 | 219 | 0.040 |
Why?
|
| Depression | 1 | 2023 | 943 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 504 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1196 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 1342 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 1330 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 1266 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2020 | 7029 | 0.020 |
Why?
|